Skip to content
Screener

Prelude Therapeutics PRLD Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$4.6MIn line
EPS-$0.13Beat by $0.14
Revenue estimate$4.6M
EPS estimate-$0.27

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$35.3M
EPS estimate-$0.16

FAQ

When did Prelude Therapeutics report Q1 2026 earnings?
Prelude Therapeutics (PRLD) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Prelude Therapeutics's Q1 2026 revenue and EPS?
Prelude Therapeutics reported revenue of $4.6M and eps of $-0.13 for Q1 2026.
Did Prelude Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $4.6M by -. EPS beat the consensus estimate of $-0.27 by $0.14.
How did Prelude Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 69.0% from $-0.42.
Where can I find Prelude Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-218162) and the 10-Q periodic report (0001193125-26-218173) directly on SEC EDGAR. The filing index links above go to sec.gov.